Our kind sponsors and partners:
At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspiration to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more—to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.
Boehringer Ingelheim’s oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through our own scientific innovation and partnerships, we are focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals. We have a clear strategy to become a leader in the field of lung cancer. Boehringer Ingelheim has successfully launched two products globally for non-small-cell lung cancer (NSCLC) that have been widely adopted and established as valuable additions to current clinical practice. Continuous insights and learnings from research and development are key parts of innovation and our way forward to advance clinical practice in lung cancer and other cancer types.
DNB is Norway's largest financial services group and one of the largest in the Nordic region in terms of market capitalization. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. Within DNB’s international strategy, healthcare is a prioritized area.
DNB is the Nordic Healthcare Bank and a top ranking healthcare bank in the US. The clients are serviced by bankers and industry experts located in New York, Oslo and Stockholm. The company assists international pharma clients with business development by actively monitoring the Nordic early-stage companies for promising technologies/products
Precision Oncology is proud to offer the first comprehensive, fully integrated oncology clinical development solution. We are devoted exclusively to oncology, and passionate about improving the lives of cancer patients. By combining the progressive science of biomarkers and analytics with our excellence in oncology clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Our unparalleled expertise, combined with management efficiency and scientific innovation, delivers the highest quality clinical trial execution with the most advanced biomarker capabilities and processes. Our established oncology site network consistently gets trials up and running within 90-days throughout the US and Europe. With a proven track record in executing complex oncology trials and seamlessly integrated lab capabilities, Precision Oncology offers an accelerated pathway to proof-of-concept and supports our clients all the way through drug registration.
The European American Enterprise Council (EAEC) is a private member-driven social enterprise and NETWORK (eight US and EU chapters).
The Chicago Cancer Cluster is a consortium that was created since 2013, bringing together the cancer centers from the 3 major Chicago Universities (Northwestern University, University of Chicago and University of Illinois in Chicago). The Robert H. Lurie Comprehensive Cancer Center of Northwestern University dedicated to discovery, advancing medical knowledge, providing compassionate, state-of-the-art cancer care, and training the next generation of clinicians and scientists while being an NCI-designated comprehensive cancer centers in Illinois—one of only 40 such centers in the country. The Cancer Center of UIC plays a unique role in the Chicago area by its commitment and ability to reach out to underserved populations of Illinois, including both urban minority and rural populations, and its commitment as a state institution to serve as a major statewide resource for cancer research and care. Withits links to regional medical campuses, at Rockford, Peoria, and Urbana, the UIC Cancer Center has developed a statewide network of excellence in cancer research and care. At the University of Chicago Medicine Comprehensive cancer from every angle. The UCCCC is recognized by the National Cancer Institute (NCI) as a preeminent leader in research to prevent cancer, elucidate its complexities, and develop novel therapies for state-of-the-art patient care. The Chicago Cancer Cluster convenes every year for the ICCS meeting during BIO and it is one of the many ways that the Chicago Universities collaborate, including being part of the Chicago Biomedical Consortium (CBC)
For more information please see cancer.northwestern.edu & chicago.medicine.uic.edu/cancercenter & cancer.uchicago.edu